Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview-Reference-Cited by-同舟云学术

Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview

Published:2013-11-21 Issue:1 Volume:5 Page:13-17
ISSN:2040-6207
Container-title:Therapeutic Advances in Hematology
language:en
Short-container-title:Therapeutic Advances in Hematology

Author:

Shen Ann Q.¹,Wilson Nicole M.²,Gleason Shannon L.¹,Khoury Hanna Jean³

Affiliation:

1. Office of Clinical Trials, Winship Cancer Institute of Emory University, Atlanta, GA, USA

2. Department of Pharmacy, Emory University Hospital, Atlanta, GA, USA

3. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365C Clifton Road, Suite C1152, Atlanta, GA 30322, USA

Abstract

Bosutinib is an orally bioavailable SRC/ABL tyrosine kinase inhibitor with activity against all phases of resistant chronic myeloid leukemia that do not express the T315I or V299L ABL kinase domain mutations. Bosutinib has a unique toxicity profile that is manageable. This paper provides an overview of bosutinib, covering pharmacodynamics and pharmacokinetic properties, results of treatment in newly diagnosed and previously treated chronic myeloid leukemia patients, as well as common side effects.

Publisher

SAGE Publications

Subject

Hematology

Link

http://journals.sagepub.com/doi/pdf/10.1177/2040620713510481

Reference8 articles.

1. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

2. Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

3. Safety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200.

4. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimisation du bosutinib dans la leucémie myéloïde chronique : recommandations du Fi-LMC (France Intergroupe des leucémies myéloïdes chroniques);Bulletin du Cancer;2024-01

2. Prévalence des Effets Indésirables des Inhibiteurs de Tyrosine Kinase Utilisés dans le Traitement de la Leucémie Myéloïde Chronique au CHU de Sidi Bel-Abbès;Annales Pharmaceutiques Françaises;2022-11

3. Bosutinib-Induced Stevens-Johnson Syndrome and Evidence of Tolerance to a Structurally Dissimilar Tyrosine Kinase Inhibitor;Cureus;2022-03-18

4. Drug-induced pleural diseases;HERALD of North-Western State Medical University named after I.I. Mechnikov;2021-12-15

5. Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors;Expert Opinion on Drug Metabolism & Toxicology;2021-11-02